Remove Doctors Remove FDA Remove Pharma Remove Safety
article thumbnail

As FDA puts CAR-T safety under microscope, researchers dig into adverse events record of BCMA therapies

Fierce Pharma

A new study examined side effect reports of BMCA immunotherapies from the FDA Adverse Event Reporting System, hoping to help inform doctors in their treatment decisions. But these immunotherapies also come with various potentially dangerous side effects. |

article thumbnail

Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug

Fierce Pharma

After a full FDA approval last week triggered Medicare coverage of Eisai and Biogen’s Leqembi, doctors are still trying to work out the logistics of testing and reimbursement. But at least two experts remain positive about the drug’s efficacy and safety profile.

Doctors 235
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Another reason change is needed at FDA? Fair balance

World of DTC Marketing

Pharma TV ads drive people online to search for more information. Safety pages on Pharma product websites continue to have high utility. As we have seen over the past few years, Pharma companies are a business, a regulated business, but still a business. This is normal, and the FDA should take note.

FDA 165
article thumbnail

Elements of a great pharma website

World of DTC Marketing

Consistently we heard that they like images of real patients or a REAL doctor with one key message communicated. 6ix: Safety information needs context. They understand that patient content could be edited to meet FDA requirements, but they like reading others’ experiences managing their health issues.

Pharma 180
article thumbnail

Healthcare Watch October 2023

PM360

Doctor Docs: Targeting Trust Between Pharma and HCPs A new study shows the crucial link in pharma marketers’ digital engagement strategy with HCPs is in jeopardy—trust. and France regarding pharma-provided digital platforms. and France regarding pharma-provided digital platforms. Three quarters of U.S.

article thumbnail

Relief for Amylyx as FDA clears controversial ALS drug Relyvrio

pharmaphorum

Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings that arrived at different conclusions about the drug. An oral version of edaravone was cleared this year.

FDA 86
article thumbnail

The debate on DTC marketing is going to heat up again

World of DTC Marketing

The FDA needs to study what people do when they see a DTC ad. Today, people don’t see a DTC TV ad and run to their doctor to ask for an Rx. 3hree: DTC marketing minimizes the side effects of prescription drugs – One of the top pages within prescription drug websites continues to be “safety information.”

Marketing 285